Effect Of Low Molecular Heparin Research Articles

Systematic review and meta-analysis of the safety and effectiveness of low molecular heparin for severe acute pancreatitis.

Because the effect of low molecular heparin (LMH) on acute ulcer and bleeding complications in patients with severe acute pancreatitis (SAP) is unclear, we investigated the safety and efficacy of early intervention with LMH in patients with SAP. Using the keywords "heparin", "low molecular weight heparin", "pancreatitis", and "severe acute pancreatitis", we searched PubMed, Medline, CNKI, etc. And select the reference documents of the comparative study of traditional treatment and low molecular weight heparin intervention. RevMan was used for the meta-analysis. A total of 8 references were included in the study, and most of them were low risk bias (medium and high quality). Meta-analysis shows that, The MHS between the two groups is statistically heterogeneous. (Chi2=19.59, I2=95%, P<0.00001), Fixed-effects model (FEM) analysis showed that the MHS of experimental subjects was obviously shorter than that of controls (Z=3.24, P=0.001); The acute physiology and chronic health score (APACHE II) of the two groups were heterogeneous (Chi2=7.24, I2=72%, P=0.03); No heterogeneity was found in the amount of bleeding (Chi2=5.83, I2=31%, P=0.21), FEM analysis showed the number of complications in the experimental group was significantly less than that in the control group (Z=2.70, P=0.007). LMH intervention can dramatically reduce the average hospital stay and complications of patients with SAP, improve treatment efficacy, and has high safety.

Efficacy of Low Molecular Heparin on Preeclampsia by Inhibiting Apoptosis of Trophoblasts via the p38MAPK Signaling Pathway.

Objective To explore the efficacy of low molecular heparin on preeclampsia by inhibiting apoptosis of trophoblasts via the p38MAPK signaling pathway. Methods A preeclampsia rat model was established, and the effects of low molecular heparin on preeclampsia via the p38MAPK signaling pathway were analyzed based on intervention of the rats with different combinations of low molecular heparin and p38MAPK signaling pathway activator. Furthermore, a hypoxia/reoxygenation model of trophoblasts in vitro was established to explore the effects of low molecular heparin on trophoblasts via the p38MAPK signaling pathway. Results After treatment with low molecular heparin, pregnant rats in the heparin group showed significantly decreased blood pressure, 24 h proteinuria, and p38MAPK protein levels in placenta tissues and decreased apoptosis rate of placenta tissue cells (all P < 0.05) and showed more fetal rats and lowered weight of them (both P < 0.05) but showed no significant change in the weight of placenta (all P > 0.05). Pregnant rats treated with low molecular heparin and p38MAPK activator showed significantly higher blood pressure, 24 h proteinuria, and p38MAPK protein levels in placenta tissues and apoptosis rate of placenta tissue cells than those of pregnant rats in the heparin group (all P < 0.05) and also showed less fetal rats and lighter fetal rats than those in the heparin group (both P < 0.05) but showed no difference with them in the weight of placenta (P > 0.05). Further analysis revealed that low molecular heparin could protect the survival and migration of trophoblasts under hypoxia/reoxygenation conditions and reduce apoptosis of them (all P < 0.05). Conclusion Low molecular heparin can alleviate preeclampsia by inhibiting the p38MAPK signaling pathway and can inhibit apoptosis of trophoblasts and promote proliferation and migration of them.

Влияние терапии низкомолекулярными гепаринами на уровень плодовой ДНК при проведении неинвазивного пренатального ДНК-скрининга

Study Objective: To evaluate the effect of low molecular heparin (LMH) therapy on non-invasive prenatal DNA screening (NIPS) for chromosomal pathologies. Study Design: cross-sectional study. Materials and Methods. We have examined two groups of pregnant women: group I included 49 patients with constantly low foetal DNA (twice lower than 4%) selected out of 1,505 women examined at Kulakov National Medical Scientific Centre of Obstetrics, Gynaecology and Perinatal Medicine of the Ministry of Health of Russia during the last 2 years. 17 women were administered LMH and 32 women did not receive it. Group II included 113 pregnant women with a normal foetal DNA fraction (at least 4%), that were selected randomly out of patients who were examined during the same period. 56 pregnant women were administered LMH and 57 were not. Next Generation Sequencing was used as an NIPS method. In order to determine the foetal DNA level, we amplified DNA loci with single nucleotide polymorphisms. Study Results. In group I (low foetal DNA fraction), where no LMH therapy was initiated, median values were 3.5% (3.2–3.8%); if LMH was administered, these values made 3.6% (3.4–3.9), while in group II — 7.7% (6.1–9.5%) and 7.9% (6.0–10.5%), respectively; no significant differences (p = 0.29 and p = 0.7, respectively) were recorded in both cases. Conclusion. Use of LMH does not affect NIPS; therefore, it is not necessary to adjust the LMH therapy in pregnant women prior to NIPS. Keywords: non-invasive prenatal DNA screening, heparin, anticoagulants, low molecular heparins, habitual abortion, pregnancy complications.

Anti-thrombotic effect of combination of low molecular heparin and Xueshuantong after replantation of amputated finger

Purpose: To study the effects of low molecular heparin combined with Xueshuantong in preventing thrombosis after replantation of amputated finger.Methods: The treatment group (38 patients) was given 4500 IU of low molecular heparin sodium i.h. (hypodermic injection), q.d.(once daily), with 200 mL of 150 mg Xueshuantong injection and 5 % glucose injection, i.v.d. (intravenous drip), b.i.d. (twice daily). The control group received low molecular heparin sodium at 4500 IU i.h., q.d. alone. Treatment was for 3 days. Thereafter, D-dimer, fibrinogen, hemoglobin, platelets, prothrombin time (PT) and blood coagulation of patients in the 2 groups before and after treatment were compared. Differences in vasospasm, vascular thrombosis, finger necrosis, therapeutic effects and adverse reactions in patients in the 2 groups after treatment were recorded.Results: There were significant improvements in fibrinogen, platelet, PT levels, and blood coagulation time after treatment, with improvements better in the treatment group than in the control group (p &lt; 0.05). Vasospasm cases (3) were lower in the treatment group than in the control group (8, p &lt; 0.05), while vascular thrombosis and finger necrosis in both groups were comparable. Therapeutic effects and recovery were better in the treatment group than in the control group (p &lt; 0.05).Conclusion: Combined injection of Xueshuantong and low molecular heparin exerts antithrombotic effects after replantation of amputated finger, improves coagulation function, and reduces incidence of vasospasm. It has better therapeutic effects than low molecular heparin, and it seems safe.Keywords: Xueshuantong, Low molecular heparin, Replantation, Amputated finger, Thrombosis

Effects of Low-Molecular Heparin on Pregnant Women with Factor V Mutation (GA Genotype)

Effects of Low-Molecular Heparin on Pregnant Women with Factor V Mutation (GA Genotype)

Clinical Efficacy of Low Molecular Heparin on Unexplained Recurrent Spontaneous Abortion.

To study the clinical effect of low molecular heparin on unexplained recurrent spontaneous abortion (URSA). A total of 120 URSA patients were collected in our hospital from October 2015 to September 2017. They were divided into two groups: control group (n = 60) and observation group (n = 60). The patients in the control group were administered with progesterone and human chorionic gonadotropin, and the observation group with low molecular heparin. Pregnancy outcomes, incidence of complications in pregnancy and adverse drug reactions were compared in the two groups. The pregnancy success rate of patients in the observation group (90.00%) is higher than that in the control group (68.33%) (p < 0.05). The incidence of complications in pregnancy in the observation group (90.00%) is lower than those in the control group (68.33%) (p < 0.05). The incidence of adverse drug reactions between the patients in the observation group (20.00%) and those in the control group (23.33%) showed no significant difference (p > 0.05). Low molecular heparin treatment can improve pregnancy success rate and reduce the incidence of complications in the URSA patients. Low molecular heparin is characterized by safety and reliability and has potential for application in clinic.

Clinical efficacy of low molecular heparin on unexplained recurrent spontaneous abortion

Objective: To study the clinical effect of low molecular heparin administered to patients with Unexplained Recurrent Spontaneous Abortion (URSA). Methodology: A total of 120 URSA patients admitted to our hospital from October 2015 to September 2017 were taken as observation subjects. They were divided into two groups based on a random number table, that is, control group (n=60) and observation group (n=60). The patients in the control group were administered with progesterone and human chorionic gonadotropin, while the patients in the observation group were administered with low molecular heparin. The two groups were compared statistically in terms of pregnancy outcomes, incidence of complications in pregnancy, and incidence of adverse drug reactions. Results: For the pregnancy outcomes, the pregnancy success rate of patients in the observation group is higher than that of the patients in the control group at 90.00% and 68.33%, respectively, indicating a significant difference (P 0.05). Conclusion: Low molecular heparin administered to the URSA patients manifests a strong clinical effect. This treatment not only improves the pregnancy success rate but also reduces the incidence of complications. Furthermore, low molecular heparin is characterized by safety and reliability, and has potential for application in clinical studies.

Effect of low-molecular heparin on therapeutic effect and renal function in patients with gastric cancer

Effect of low-molecular heparin on therapeutic effect and renal function in patients with gastric cancer

Clinical study of low molecular heparin combined with mesalazine in treatment of patients with active ulcerative colitis

Objective To investigate the clinical effect of low molecular heparin combined with mesalazine in patients with active ulcerative colitis(UC). Methods 90 cases of patients with UC were randomly divided into three groups:A group,B group and C group,with 30 cases in each group.A group was given oral treatment with sulfasalazine enteric-coated tablets,B group was given oral treatment with mesalazine and C group was given low molecular heparin calcium combined with mesalazine(4100 iu, 1/d).The three groups were treated for 2 weeks.Coagulant function index such as activated partial prothrombin time(APTT),fibrinogen(FIB),platelet count(PLT),platelet maximum aggregation rate(PAG(Max)),D-dimer(D-D),C-reactive protein(CRP) were detected in the two groups before and after treatment of 7 and 1 4 d.Mayo disease activity index score was also recorded before and after treatment of 7 and 14d.And the differences among three groups were compared .Results There were significant differences in APTT,FIB,PLT and PAG(Max)after 7d,14d treatment among A,B and C groups(7d:F value were 17.652,12.427,42.873,14.318 respectively;14d:F value were 43.804,139.172,51.932,79.440 respectively,all P value< 0.05).APTT of C group after 7d,14d[(36.32±3.56)μg/m L,(40.15±4.24)μg/m L]were higher than B group[(32.14±2.86)μg/m L,(33.04±3.32)μg/m L]and A group[(31.82±3.36)μg/m L,(32.15± 3.24)μg/m L];FIB of C group after 7d,14d[(4.07±0.41)g/L,(3.14±0.28)g/L]were lower than B group [(4.47±0.40)g/L,(4.06±0.33)g/L]and A group[(4.58±0.44)g/L,(4.23±0.37)g/L];PLT of C group after 7d,14d[(262.22±60.61)×109/L,(201.38±49.42)×109/L]were lower than B group[(296.34±63.51)× 109/L,(253.25±55.47)×109/L]and A group[(301.71±70.62)×109/L,(262.05±64.11)×109/L];PAG (Max)of C group after 7d,14d[(0.46±0.08),(0.30±0.05)]were lower than B group[(0.57±0.10),(0.46±0.06)]and A group[(0.59±0.12),(0.51±0.08)].There were significant differences in CRP,D-D after 14d treatment among A,B and C groups(F value were 91.967,139.172 respectively,all P value<0.05).CRP of C group after 14d[(7.50±1.35)mg/L]were lower than B group[(10.80±1.37)mg/L]and A group[(12.12±1.64)mg/L];DD of C group after 14d[(0.26±0.02)mg/L]were lower than B group[(0.47±0.03)mg/L]and A group[(0.51±0.04)mg/L].There were significant differences in Mayo index score,△Mayo index score after 14d treatment among A,B and C groups(F value were 182.170,89.802 respectively,all P value<0.05).Mayo index score of C group after 14d(1.51±0.33) were lower than B group(2.93±0.46)and A group(3.42±0.63);.△Mayo index score of C group after 14d(5.67±1.60)were lower than B group(4.25±1.32)and A group(3.79±1.21);Pearson correlation analysis showed that△Mayo Mayo index score were positively correlated with PAG(Max) reduction△PAG(Max),△D-D,△CRP,△PTL(r value were 0.616,0.702,0.734,0.569,respectively,all P< 0.05).Multiple stepwise linear regression analysis showed that△PAG(Max),△D-D,△CRP,△PTL were closely related to△Mayo Mayo index score(partial regression coefficient were 4.209,2.451,0.801 respectively;t value were 7.890,4.787,2.201,respectively,all P<0.05). Conclusion The clinical effect of low molecular heparin combined with mesalazine in patients with active ulcerative colitis is effective,and the method can significantly improve the inflammation in patients with UC and high coagulation state,improving the clinical symptoms is better than the single drug,and worth clinical recommendations. Key words: Colitis; Ulcerative; Low molecular heparin; Mesalazine

The effect of low molecular heparin on the prognosis of severe pneumonia in elderly patients

To investigate the effect of low molecular heparin on degree of severity and prognosis of severe pneumonia in elderly patients. A prospective randomized control study was conducted. During October 2009 to July 2013, 63 patients over 65 years old and suffering from severe pneumonia were enrolled. Patients were grouped into control or treatment group randomly. The control group (n=36) received routine treatment, while low molecular heparin 4 kU once a day was added in treatment group (n=39) for 7 days. Acute physiology and chronic health evaluationII(APACHEII) score, coagulation function indexes, blood gas analysis, arterial lactic acid at 1, 3, 7 days after treatment, and length of mechanical ventilation, days of stay in ICU, and 7-day mortality were compared between both groups. The basic data and APACHEII score had no difference between two groups (all P>0.05). Bleeding events occurred on day 1, 3, 7 in 1, 1, 2 patients in control group, respectively, and 0, 1, 3 cases in treatment group. There was no difference in APACHEII score on day 1 and day 3 between control group and treatment group (1 day: 19.33 ± 5.90 vs. 20.31 ± 4.97, t=0.775, P=0.441; 3 days: 18.69 ± 4.88 vs. 17.41 ± 3.83, t=1.272, P=0.207). APACHEII score on day 7 in treatment group was significantly lower than that in control group (13.92 ± 3.61 vs. 16.20 ± 4.23, t=2.480, P=0.016). There was no significant difference in coagulation function indexes during observation period between two groups (all P>0.05). The blood gas analysis showed that only arterial partial pressure of oxygen (PaO2) 7 days after treatment in treatment group was significantly higher than that in control group (110.52 ± 28.57 mm Hg vs. 95.47 ± 24.17 mm Hg, t=-2.354, P=0.022). There was no significant difference in 7-day mortality between two groups. The mechanical ventilation time in treatment group was slightly shorter than that in control group (147.45 ± 111.45 hours vs. 192.20 ± 115.57 hours, t=1.704, P=0.093). The length of stay in ICU in treatment group was significantly shorter than that in control group (13.77 ± 5.77 days vs. 17.22 ± 6.21 days, t=2.497, P=0.015). In elderly patients suffering from severe pneumonia, low molecular heparin may reduce APACHEII score, shorten mechanical ventilation time and length of ICU stay, and the prognosis may be improved.

Observation on clinical effects of low molecular heparin combined with phentolamine in treatment of cor pulmonale with refractory heart failure

Objective To observe the clinical effects of low molecular heparin combined with phentolamine in treatment of cor pulmonale with refractory heart failure.Methods We analyzed the clinical effects of the low molecular heparin combined with phentolamine to the routine complex treatment (observation group,n=35) or the routine complex treatment (control group,n=35) for treatment of 70 patients with cor pulmonale with refractory heart failure in our hospital from May 2010 to November 2012.Results After treatment,whole blood contrast was (7.09 ± 1.25),hematocrit was (0.541 ± 0.114),blood plasma viscosity was (1.62 ± 0.07),hemoglobin was (121.31 ± 25.22) g/L,and clinical effect rate was 94.28％ in the observation group.Whole blood contrast was (8.87 ± 1.13),hematocrit was (0.592 ± 0.125),blood plasma viscosity was (1.83 ± 0.11),hemoglobin was (136.36:±:36.63) g/L,and clinical effect rate was 77.14％ in the control group.The clinical effects and blood rheology in the observation group were significantly better than those in the control group.Conclusion The low molecular heparin combined with phentolamine in treatment of cor pulmonale with refractory heart failure has definite efficacy and safety.It is worthy to be popularized in clinic. Key words: Low molecular heparin; Phentolamine; Cor pulmonale; Refractory heart failure

股関節および膝関節全置換術後の静脈血栓塞栓症(VTE)に対する低分子量ヘパリン(RP54563)の予防効果

股関節および膝関節全置換術後の静脈血栓塞栓症(VTE)に対する低分子量ヘパリン(RP54563)の予防効果